| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10786482 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US9808442 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US10154987 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US9669008 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US10772868 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US11040023 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US11141405 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US11173141 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
| US10039745 | AZURITY | Enalapril formulations |
Mar, 2036
(12 years from now) | |
Epaned is owned by Azurity.
Epaned contains Enalapril Maleate.
Epaned has a total of 9 drug patents out of which 0 drug patents have expired.
Epaned was authorised for market use on 20 September, 2016.
Epaned is available in solution;oral dosage forms.
Epaned can be used as treatment of hypertension; method of treating left ventricular dysfunction; method of treating hypertension; method of treatment of heart failure; treatment of heart failure, method of treatment of heart failure; treatment of heart failure; method of treating hypertension; method of treating left ventricular dysfunction; treatment of hypertension.
The generics of Epaned are possible to be released after 25 March, 2036.
Drugs and Companies using ENALAPRIL MALEATE ingredient
Market Authorisation Date: 20 September, 2016
Treatment: Method of treatment of heart failure; Treatment of heart failure; Method of treating hypertension; Method of treating left ventricular dysfunction; Treatment of hypertension
Dosage: SOLUTION;ORAL
EPANED family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic